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Non–muscle-invasive bladder cancers (NMIBCs) are tumors confined to the mucosa or the mucosa/submucosa.
An important challenge in treatment of NMIBC is both high recurrence and high progression rates. Consequently,
more efficacious intravesical treatment regimes are in demand. Inhibition of the cell’s DNA repair systems is a new
promising strategy to improve cancer therapy, and proliferating cell nuclear antigen (PCNA) is a new promising
target. PCNA is an essential scaffold protein in multiple cellular processes including DNA replication and repair.
More than 200 proteins, many involved in stress responses, interact with PCNA through the AlkB homologue 2
PCNA-interacting motif (APIM), including several proteins directly or indirectly involved in repair of DNA interstrand
crosslinks (ICLs). In this study, we targeted PCNA with a novel peptide drug containing the APIM sequence, ATX-
101, to inhibit repair of the DNA damage introduced by the chemotherapeutics. A bladder cancer cell panel and
two different orthotopic models of bladder cancer in rats, the AY-27 implantation model and the dietary BBN
induction model, were applied. ATX-101 increased the anticancer efficacy of the ICL-inducing drug mitomycin C
(MMC), as well as bleomycin and gemcitabine in all bladder cancer cell lines tested. Furthermore, we found that
ATX-101 given intravesically in combination with MMC penetrated the bladder wall and further reduced the tumor
growth in both the slow growing endogenously induced and the rapidly growing transplanted tumors. These
results suggest that ATX-101 has the potential to improve the efficacy of current MMC treatment in NMIBC.
Translational Oncology (2014) 7, 812–823co-funded this study. M.O. is an inventor, minority shareholder, and chief scientific
officer (CSO) in the company (Patent Application No. PCT/GB2009/000489
“New PCNA interacting motif”, filed on February 20, 2009). There are no further
patents, products, development, or marked products to declare.
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Non–muscle-invasive bladder cancer (NMIBC) accounts for 60% to
80% of newly diagnosed bladder cancer. NMIBC with current
treatment still has a high probability for relapse, ranging from 31% to
78% after 5 years. A more serious challenge in these patients is
progression rates up to 45% for high-risk disease, i.e., submucosal
invasion and/or carcinoma in situ. Consequently, new intravesical
treatment regimes are in demand [1,2].
Mitomycin C (MMC) alkylates and cross-links DNA and is among
the most commonly used chemotherapeutic agent in NMIBC. The
DNA interstrand crosslinks (ICLs) introduced by MMC are highly
cytotoxic lesions. The severity of ICLs is due to involvement of both
DNA strands and thus subsequent arrest of both replication and
transcription. To repair ICLs, complex mechanisms involving
translesion synthesis (TLS), homologous recombination, mismatch
repair, nucleotide excision repair, several endonucleases, and Fanconi
anemia proteins are required [3,4].
Proliferating cell nuclear antigen (PCNA) is an essential organizer
“hub” protein in DNA replication and repair [5]. PCNA has also
recently been linked to various cytosolic functions such as regulation
of apoptosis, metabolism, and antitumor immunity [6–8]. More than
400 proteins may interact with PCNA using two binding motifs,
PCNA-interacting peptide (PIP)‐box [9] and AlkB homologue 2
PCNA-interacting motif (APIM) [10]. We and others have
demonstrated that functional interaction with PCNA is mediated
through APIM in several DNA repair proteins important for repair of
ICLs [10–14]. Hence, several lines of evidence suggest that PCNA
interactions through the APIM sequence are vital during cellular
stress. Therefore, blocking these interactions by targeting PCNA with
APIM-containing peptides may impair the cell's ability to survive
genotoxic stress introduced by chemotherapeutics and radiation
therapy. A novel cell penetrating APIM-containing peptide, ATX-
101, targets PCNA and reduces the binding of APIM-containing
proteins to PCNA [15], thus inducing apoptosis and enhancing the
efficacy of chemotherapeutic drugs in various cancer cell lines, in
primary cancer cells ex vivo, and in xenograft models [15]. In this
study, we examined if targeting PCNA with ATX-101 in bladder
cancer cell lines and animal models increased the efficacy of
chemotherapeutics, and if ATX-101 could penetrate the bladder
wall and thus have the potential to increase the efficacy of intravesical
MMC treatment in NMIBC.
Materials and Methods
Peptide
ATX-101 peptide [15] was purchased from Innovagen, (Lund, Sweden)
Chemotherapeutics
MMC (Medac, Chicago, IL, USA), bleomycin (Baxter Medical,
CA, USA), and gemcitabine (Santa Cruz Biotechnology Inc, Los
Angeles, CA, USA) were used in cell survival studies and in animal
models as described below and in Figures 1, 2, and 4.
Cell Lines
TCCSUP, HT-1197, Um-Uc-3, HT-1376, RT4, T-24, and 5367,
all urothelial carcinomas from the bladder cancer cell panel ATCCNo.
TCP-1020, were grown as recommended. AY-27, a syngeneic rat
bladder cancer cell line, was kindly provided by Professor S. Selman,
Department of Urology,Medical College of Ohio, Toledo, OH, USA.
Growth conditions were as previously described [16].Cell Survival Assay
Cells were seeded into 96-well plates, and different doses of ATX-
101 and chemotherapeutic drugs were added. Cells were exposed
continuously and harvested everyday for the next 4 days using the 3-
(4.5-dimethylthiazol-2-yl)-2.5 diphenyltetrazolium bromide assay as
previously described [15].
Orthotopic Rat Bladder Cancer Models
The AY-27 model is previously described [17,18] The BBN model
is based on N-butyl-N-(4-hydroxybutyl)-nitrosamine–induced blad-
der cancers as described in [19,20]. Briefly, endogenous tumors were
induced by continuous exposure of BBN (0.05%; Sigma, St. Louis,
MO, USA) in the drinking water for 12 weeks. The animals were
thereafter given normal tap water ad libitum and monitored daily for
general health status and treated 33 days after ended BBN exposure.
Animals and Ethics
Female Fischer CDF344 rats (Harlan Laboratories, Blackthorn, United
Kingdom) were used for all experiments at the Unit of Comparative
Medicine, Norwegian University of Science and Technology (NTNU).
The animal experiments were approved by the Norwegian National
Animal Research Authority [Forsøksdyrutvalget (FDU); FOTS applica-
tions 4005, 4408, 4669, 4962, 4822, and 5502]. The rats were
anesthetized subcutaneously with a mixture (0.35-0.40 ml/100 g body
weight) containing haloperidol (5mg/ml; Janssen (Beerse, Belgium); 17%
vol/vol), fentanyl (50 μg/ml; Actavis (Parsippany, NJ, USA); 25% vol/
vol), and midazolam (5 mg/ml; Actavis; 25% vol/vol) in water. Rats
received temgesic (0.33 ml/200 g body weight) and subcutaneous
injection of NaCl (0.9%, 5-10 ml) after instillation of cells when needed,
as judged by their condition.
Experimental Treatment Groups
The rats were treated 14 days after instillation of AY-27 cells or 33 days
after ended 12-week exposure to BBN based on previous experience
[16,20] and unpublished data. MMC (1mg/ml) or bleomycin (1 mg/ml)
was used for intravesical treatment, either alone or in combination with
ATX-101 (30 μM). For the rats treated twice, treatments were performed
on days 14 and 28. Controls were not treated (untreated) or sham treated
withNaCl (0.9%). The bladder waswashedwithNaCl (0.9%, 1 × 0.3ml)
before instillation of the treatment solution (0.3 ml). The animals were
turned every 15 minutes during the treatment. After 1 hour, the bladders
were washed with NaCl (0.9%, 2 × 0.3 ml).
One hundred fifteen rats representing seven experimental/biologic
replicas using the AY-27-model are included in the study and shown in
Figure 4. Six rats are not included in the study due to death of unknown
causes (five rats) or during anesthesia (one rat). Five rats had transparent
and macroscopically normal bladders, i.e., they likely did not develop
tumor after instillation of tumor cells (“no takes”). These rats were in
groups treated with only NaCl (1 rat) and ATX-101 alone (all four rats
below the broken line), as seen in Figure 4.
Thirty-one rats representing one experiment/biologic replica using
the BBN model are included in the study and shown in Figure 4. All
of these rats established tumor. One rat was not included in the study
due to death of unknown cause.
We could not detect any side effects of the combination of MMC and
ATX-101 compared to rats treatedwithMMC,ATX-101, orNaCl alone.
Termination
The rats from the AY-27 model were sacrificed 19 and 41 days after
treatment, unless earlier in cases where the animals became ill
Figure 1. ATX-101 alone and in combination with MMC, bleomycin, and gemcitabine inhibits growth of human and rat bladder cancer cel
lines. Cell growth over time of seven different human bladder cancer cell lines (TCCSUP, HT-1197, HT-1376, Um-Uc-3, 5637, T-25, and
RT4) and one rat bladder cancer cell line (AY-27) was measured with 3-(4.5-dimethylthiazol-2-yl)-2.5 diphenyltetrazolium bromide assays
Growth of unexposed cells ( ) as well as cells treated with ATX-101 [2 μM ( ), 4 μM ( ), and 6 μM ( )] and chemotherapeutic agents
(MMC, bleomycin, or gemcitabine) alone ( ) or in combination with ATX-101 ( ) is marked. Data of one representative experiment of a
least two are shown. Continuous exposure to (A) ATX-101, (B) ATX-101 and MMC alone or in combination, (C) ATX-101 and bleomycin
alone or in combination, and (D) ATX-101 and gemcitabine alone or in combination.
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tumors (BBN model) were sacrificed 115 days after treatment. The
bladders were opened, weighed, and macroscopically examined before
mounting and transferring to formalin (4%) for fixation, paraffin-
embedding, and later histopathologic examination.Statistics
Animals treated with bleomycin alone and bleomycin/ATX-101
showed a close to normal distribution; thus, a one tailed Student’s t test
was used for this experiment. For the animals treated with MMC alone
andMMC/ATX-101, an overall larger effect of treatments was observed,
Figure 2. ATX-101 penetrates bladder epithelia and bladder cancer tissue. Penetration of FAM-tagged ATX-101 (30 μM; shown in green in
the left panel) in bladder epithelia and cancer tissue after 1 hour intravesical instillation in rat bladders is shown. Frozen sections of ATX-
101–FAM–treated bladders are DNA-stained with DAPI (shown in blue) and evaluated by confocal microscopy using a 20× dry objective.
(A) Normal bladder. (B) Tumor-bearing bladder. Bars, 100 μM.
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weight population. As verified macroscopically and by histopathologic
examinations (Figure 3 and Table 1), the low weight population had
stopped growing, whereas in the highweight population, the tumors were
in active growth and this was the cause of the weight gain (not edema or
inflammation). Therefore we used the χ2 test on these two populations.
In the AY-27 model, the “not growing” population was classified as the
bladders below 0.23 g, based on the largest bladder in the low weight
population at day 41 in the 2× treated MMC/ATX-101 group. In the
BBNmodel, the “not growing” bladders had weights below 0.17 g. This
is illustrated as broken lines in Figure 4.
Uptake Study
After intravesical instillation of ATX-101 (30 μM, 0.3ml, 1 hour), the
solutions were retrieved from the bladders, diluted (1:5) in HCl (0.2%),
and analyzed for full-length peptide on aWaters Acquity I-Class UPLC –
TQ-S triple quadrupole mass spectrometer operated in positive
electrospray mode. The HPLC column was a Zorbax C18 300SB
Poroshell with dimensions of 2.1 × 75 mm. Column temperature was
40°C, and the flow rate was 0.4 ml/min. Mobile phases were 0.2% acetic
acid + 0.01% trifluoroacetic acid in mass spectrometry (MS) grade water
(A) and 0.2% acetic acid + 0.01% trifluoroacetic acid in MS grade
acetonitrile (B). The following mobile phase gradient was used: 0 to 0.5
minutes, 0% B; 0.5 to 3 minutes, from 0% to 30% B; 3 to 3.5 minutes,from 30% to 100%B; 3.5 to 4minutes, 100%B; 4 to 4.1minutes, from
100% to 0% B, and 6 minutes. The Multiple Reaction Monitoring
(MRM) transition 409.1→438.5 was used as a target ion for
quantitation, and the MRM transitions 460.3→501.1 and
613.3→84.0 were used as qualifier ions with expected ratios of 0.3 and
0.6, respectively, to the target ion. Ion source settings were 1000 l/h,
temperature of 500°C, and capillary cone voltage of 3 kV.
Penetration Study
After instillation of ATX-101 fluorescently tagged with either
fluorescein (FAM) or cyanine-7 (Cy7) (30 μM, 0.3 ml, 1 hour), the
bladders were washed with NaCl (0.9%, 3 × 0.3 ml). Frozen sections
of ATX-101–FAM–treated bladders were DNA stained with 4′,6-
diamidino-2-phenylindole (DAPI) and examined by confocal
microscopy. Live animal imaging during instillation of ATX-101–
Cy7 was performed using the Li-Cor small animal in vivo imaging
system (170 μM resolution, Odyssey, CLx). After 1 hour, ATX-101–
Cy7 was washed, and the imaging process was repeated.
Immunofluorescence and Confocal Imaging
Bladder cancer cells were grown on glass bottom dishes and stained
with anti-PCNA (PC10; Santa Cruz Biotechnology Inc) and Alexa Fluor
532 goat anti-mouse (Invitrogen, Carlsbad, CA, USA) antibodies and
DRAQ5 (eBioscience, San Diego, CA) as described [15]. The relative
Figure 3. Macroscopic and HES-stained images of recovered normal and cancer-containing rat bladders (AY-27 model). (A) Images of
opened and mounted rat bladders recovered from animals with different tumor grades as evaluated by histopathology. Bladder weights
are given. (B) Images of HES-stained rat bladders (20×).
Translational Oncology Vol. 7, No. 6, 2014 Improved efficacy of MMC treatment in NMIBC models Gederaas et al. 817
818 Improved efficacy of MMC treatment in NMIBC models Gederaas et al. Translational Oncology Vol. 7, No. 6, 2014intensities of PCNA in cytosol/nuclei were calculated using mean
region of interest containing at least 400 pixels using the Zeiss LSM
510 software.
Histopathologic Assessment
Slicing of freeze sections, paraffin embedding, and hematoxylin-
erythrosine-saffron (HES) staining were done using standard procedures
at the Cellular and Molecular Imaging Core Facility, NTNU. Frozen
tissues were Optimal Cutting Temperature compound (OCT)-
embedded, cut in 4-μm-thick sections, counterstained with DAPI
(Vector, Burlingame, CA, USA), and examined in a Zeiss LSM 510 laser
scanning microscope. The HES-stained tissues were examined for
morphologic changes by a uropathologist using a light microscope.
Immunohistochemistry: Formalin-fixed paraffin-embedded sectionswere
deparaffinized before heat-induced epitope retrieval was performed using
DAKO Target Retrieval Solution (S1699) and DAKO PT Link (Dako,
Glostrup, Denmark). The sections were incubated for 40 minutes at
room temperature with the proliferationmarker anti-Ki67 (1:50; Abcam,
Cambridge, UK; ab16667), the apoptosis marker anti–cleaved caspase-3
(Asp175; 1:100; Cell Signaling Technology, Beverly, MA, USA; #9661),
and the senescence marker anti-p21 (10 μg/ml; Abcam; ab18209).
Immunohistologic staining was performed using a DAKO Autostainer
and DAKO EnVision Detection System with DAB+ chromogene.
Sections were counterstained with hematoxylin. The immunohisto-
chemistry-stained tissues were examined by a uropathologist.Results
ATX-101 Increases the Sensitivity to Chemotherapeutic Drugs
in Several Bladder Cancer Cell Lines
Prior studies have demonstrated that APIM peptides sensitize
several different, but not all, cancer cell lines to chemotherapeutic
agents [10,15]. To determine if bladder cancer is a good indication,
we tested a panel of human bladder cancer cell lines for growth after
exposure to ATX-101 alone in combination with three functionally
different chemotherapeutics that each induces different DNA lesions.
We found that three of the seven cancer cell lines tested (HT-1376,
Um-Uc-3, and RT4) in addition to the rat bladder cancer cell line
AY-27 were highly sensitive to ATX-101 alone (Figure 1A). In
addition, all the cell lines showed an increased sensitivity toward all
the three cytotoxic compounds tested (gemcitabine, a nucleoside
analog; bleomycin, a DNA strand break inducer; MMC, introducing
ICLs) when combined with ATX-101 (Figure 1, B to D, black
circles). These data suggest that treatments of bladder cancer could
benefit from treatment with ATX-101 in combination with several
different chemotherapeutics.Figure 4. Inhibition of tumor growth in two orthotopic bladder cance
combination with bleomycin andMMC. Rats were treated once or twi
mM) or bleomycin (1 mg/ml, 75 μM) alone or in combination with A
treatment group is given below the x-axis. Animals that died/were sac
The AY-27-model: bleomycin alone and in combination with ATX-101.
The control groups (untreated, 0.9% NaCl, and normal bladders) are
harvested and evaluated for tumor presence by total weight at day 1
with MMC alone or in combination with ATX-101. Animals were s
presence by total weight 115 days post-treatment. Error bars represen
tailed Student’s t test. (B and C) Broken lines divide the actively grow
P values between the different groups (described in the Materials anATX-101 Penetrates into the Bladder Wall
The ability of a drug to penetrate the bladder wall mucosa as well as
underlying tissue is imperative for its efficacy in bladder cancer
therapy. ATX-101 is rapidly imported into cells in cell cultures [15].
To examine ATX-101's penetration into the bladder wall, we
measured residual full-length ATX-101 in retrieved solution after
intravesical bladder instillation by liquid chromatography - mass
spectrometry/mass spectrometry (LC-MS/MS). We found an
approximately 10-fold reduction in full-length peptide: 53 μg/ml
ATX-101 in instilled solution versus 5.7 ± 1.6 μg/ml in retrieved
solutions (n = 8). The closed catheter was kept in place during
instillation, and no leakage was observed. Urine dilution of the
samples could account for up to two- to three-fold reduction in
peptide concentrations, and ATX-101 has a T1/2 of 5.5 hours in
undiluted urine (human) in vitro (data not shown). Therefore, the
data suggested that ATX-101 penetrates the bladder wall, and to
confirm this, we instilled fluorescently tagged ATX-101 (ATX-101–
FAM). Confocal images confirmed that ATX-101 was distributed
throughout the bladder epithelia and penetrated into the muscular
layer. Furthermore, ATX-101 efficiently penetrated into tumor-
containing areas (Figure 2, A and B).
The ability of ATX-101 to penetrate the bladder wall was also
examined by live animal imaging. Fluorescently tagged ATX-101 (ATX-
101–Cy7) could clearly be detected in the bladder area, whereas no
diffusion outside this region of the animal was observed during the
instillation (data not shown). ATX-101–Cy7 could also be detected in the
same region of the animal after washing of the bladder with saline,
supporting the presence of residual peptide in the bladder wall.
ATX-101 Potentiates the Efficacy of Bleomycin and MMC in
Two Orthotopic Rat Bladder Cancer Models
Next, we examined the anticancer effect of ATX-101 in
combination with bleomycin and MMC in the AY-27 syngeneic
rat orthotopic bladder cancer model. The rats were treated once
intravesically with chemotherapeutics alone or in combination with
ATX-101. The tumor load in the bladders 19 and 41 days after
treatment was evaluated by total bladder weight in combination with
macroscopic (Figure 3A) and histopathologic examination (Table 1
and Figure 3B). We observed reduced tumor load in animals treated
with ATX-101 in combination with bleomycin (Figure 4A) or MMC
(Figure 4B) compared to treatment with bleomycin or MMC alone.
Reduced tumor load in the groups receiving the combination of
MMC/ATX-101 was observed both after 19 and 41 days.
Additionally, we treated two groups twice (2×) with the combination
MMC/ATX-101 or MMC alone and examined the groups 41 days
after the first treatment. Again, increased efficacy was observed in ther models in immune-competent rats after treatment of ATX-101 in
ce (2×) through intravesical instillation (1 hour) of MMC (1 mg/ml, 3
TX-101 (30 μM). The number of animals (n) in each experimental
rificed before termination date are marked with open symbols. (A)
(B) The AY-27-model: MMC alone and in combination with ATX-101.
the same in A and B. Animals were sacrificed, and bladders were
9 or 41 post-treatment. (C) The BBN model: intravesical treatment
acrificed, and bladders were harvested and evaluated for tumor
t SEM. Statistics: (A) P values were calculated by the unpaired, two-
ing and not growing tumors, and the χ2 test was used to calculate
d Methods section).
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supporting the results from the animals treated once (Figure 4C ). We
could not detect any single agent activity of ATX-101 neither after
one or two treatments nor after increasing the dose 10-fold
(Figure 4C ) even though ATX-101 had single agent activity on
AY-27 in cell culture (Figure 1).
The AY-27 model is based on instillation of a cancer cell line and it
can, therefore, be considered a “monoclonal” rapidly growing tumor
model. We also wanted to examine if ATX-101 increased the efficacy
of MMC in a more “endogenous” slow growing tumor model. In this
model, tumors are induced by adding BBN to the drinking water.
Intravesical treatment was done with MMC alone or in combination
with ATX-101 in exactly the same manner as in the previous AY-27
model. These rats were then kept for an additional 115 days before
termination of the study. Similar to the results from the AY-27
model, ATX-101 in combination with MMC reduced the tumor
growth compared to MMC alone (P = .007; Figure 4D). Thus, these
two models together strongly suggest that ATX-101 potentially
improves the anticancer efficacy of MMC.
Histopathologic Examination Suggests that ATX-101 Potentiates
the Effect of Intravesical Chemotherapeutics
The macroscopic (Figure 3A) and histopathologic examination
(Figure 3B and Table 1) verified that the bladder weight
measurements corresponded overall well with the tumor status ofthe bladders. All animals not treated with MMC or MMC/ATX-101
developed T2-3G3 in the AY-27 group and Ta/1G2-3 in the BBN
group (Table 1, A and B).
One rat in each of the MMC/ATX-101 combination groups (both
BBN and AY-27) contained no detectable tumors, only metaplasia as
determined histopathologically (Table 1). The macroscopic evalua-
tion of these bladders at time of harvest suggested that the bladder
wall was less transparent than normal bladders supporting that there
had been a tumor previously.
The combination treatment of MMC/ATX-101 in the BBNmodel
resulted in mostly TaG1-classified tumors, whereas MMC treatment
alone resulted in more high-grade tumor classifications, ranging from
TaG1 to T3G3 tumors (Table 1B). The histologic evaluation of the
bladders from the AY-27 studies had a similar tendency, i.e., less
invasive/smaller bladder tumors in the group treated with the
combination of MMC/ATX-101 (Table 1, A and C ).
The data of bladder weights (Figure 4, B and C ) suggests that
small tumors below the broken line have stopped growing as there is
no increase in bladder weights observed between days 19 and 41. To
test this, we selected three animals from the groups treated twice with
MMC or MMC/ATX-101 and examined them for caspase-3, Ki67,
and p21 levels. One rat treated twice with MMC/ATX-101 was
tumor free and was negative for caspase-3 and p21. Tumors in the
other bladders containing small tumors were positive for caspase-3
and expressed low levels of p21 and Ki67, supporting lack of growth
Figure 5. PCNA levels in human bladder cancer cell lines do not correlate with ATX-101 sensitivity. (A) Confocal fluorescence images of
immunofluorescently stained PCNA (red) in the human bladder cancer panel. The images are taken the same day using the same settings
on the microscope; thus, fluorescence intensity directly corresponds to different levels of PCNA. (B) Left y-axis: relative levels of PCNA in
the cytosol over PCNA in the nucleus in the different cell lines. Mean intensities of cytosolic and nuclear PCNA in four regions of interest in
each cell, from 13 cells, from each cell line are measured. Values are normalized against the value in RT4 (the cell line with lowest ratio of
cytosolic /nuclear PCNA; gray bars, mean ± SEM, n = 52). Right y-axis: sensitivity toward ATX-101 as a single agent. The bladder cancer
cell lines were classified as high, medium, or low according to their sensitivity toward ATX-101 based on results from the cell survival
assays (Figure 1). A graph indicating sensitivity is shown. (C) Doses of MMC, bleomycin, and gemcitabine giving 30% to 50% (40 ± 10)
reduction in growth in the different cell lines (from data in Figure 1 and biologic replicas) are summarized and compared to sensitivity
toward ATX-101 and PCNA content in the cells. (B and C) Cell lines in red are sensitive to ATX-101 and cell lines with high total levels of
PCNA are shown with gray background.
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positive for Ki67, supporting active growth.
The Sensitivity of Bladder Cancer Cells to ATX-101 Is Not
Linked to PCNA Levels
PCNA is often used as a marker for proliferation and is often
overexpressed in cancer cells [21]. Additionally, PCNA has vital roles
in processes frequently deregulated in cancer, e.g., DNA replicationand repair/chromatin remodeling and apoptosis [5,6,15]. It is also
reported that the expression of PCNA is upregulated in BBN-induced
bladder tumors in rats similar to what is found in superficial bladder
cancers in humans [22]. Thus, intracellular levels of PCNA [23] and/
or localization of PCNA (i.e., levels in cytosol vs nuclei) could
potentially be a biomarker for whether the bladder cancer cells are
sensitive to ATX-101 or not. Therefore, we examined the PCNA
content and distribution in the bladder cancer panel and compared it
Figure 6. Model. PCNA (blue ring) is an essential cellular protein controlling cellular homeostasis. “Housekeeping” proteins such as
proteins necessary for replication (gray proteins) interact with PCNA through a sequence known as the PIP box (A, left). Upon cellular
stress such as DNA damage, PCNA is posttranslationally modified (“PTMs”, addition of black groups on PCNA) and this targets a stress
switch increasing the affinities for APIM-containing proteins (yellow, pink, and red proteins; A, right). Upon targeting PCNA with peptides
containing the APIM motif such as ATX-101 (in red), APIM-containing proteins are prohibited from PCNA interaction (B). This impairs
cellular homeostasis and renders cancer cells hypersensitive to a multiple of chemotherapeutic drugs.
822 Improved efficacy of MMC treatment in NMIBC models Gederaas et al. Translational Oncology Vol. 7, No. 6, 2014to sensitivity against ATX-101 and the other chemotherapeutics. We
found that the sensitivity toward ATX-101 (line in Figure 5B, right
axis; cell lines marked in red are ATX-101 sensitive) is not correlated
to the ratio of cytosolic versus nuclear PCNA (bars in Figure 5B, left
axis) or to total levels of PCNA in the cells (cell lines with gray
background). Furthermore, there is no correlation between high
PCNA content (gray background), ATX-101 sensitivity (red), and
the cell's sensitivity to MMC, bleomycin, and gemcitabine
(summarized in Figure 5C ).
Discussion
We found no correlation between bladder cancer cells sensitivity
toward ATX-101, or the other chemotherapeutics tested, and PCNA
levels. Experiments have shown that APIM peptides co-immunopre-
cipitated a subfraction of PCNA with a different isoelectric profile
compared to the isoelectric profile of total PCNA in cells [10]. During
replicative stress/arrest, PCNA is posttranslationally modified
enabling a switch from the replicative to the TLS polymerases
[5,24]. We believe that the stress levels in the cancer cells and thus the
posttranslational modifications on PCNA determine the sensitivity of
cells toward ATX-101 and not the total level of PCNA or ratios of
PCNA in cytosol/nucleus. Nonmalignant cells are not to the same
degree “stressed” and therefore only require housekeeping proteins forcontinued survival, whereas malignant cells are in a stressed state and
therefore critically dependent on stress response proteins [25]. This
explains the selectivity of ATX-101's ability to selectively target cancer
cells and the low overall cytotoxicity in vivo [15].
A model suggesting a switch from normal housekeeping proteins
binding PCNA through the PIP box to stress response proteins
binding through APIM during stress is illustrated in Figure 6. The
molecular mechanism of how ATX-101 sensitizes cancer cells toward
chemotherapeutics is multimodal and based on ATX-101's ability to
target PCNA and inhibit interactions between APIM-containing
proteins and PCNA [15]. It has been shown that APIM-PCNA
interaction is important for the efficacy to repair specific DNA lesions
[10,11] and to restart stalled replication forks [12,13]. Recently, the
APIM-PCNA interaction was shown to be important for the
functionality of TFII-I in TLS [14]. Additionally, attenuated
interaction of PCNA with other APIM-containing proteins such as
the homologous recombination protein RAD51B, Topo II alpha, and
the translesion polymerase POLζ will likely also reduce the “stressed”
cancer cells' ability to repair DNA lesions.
Many new cancer drugs are selected for their cytotoxic effects on
the rapidly proliferating cancer cell lines used in preclinical
experiments. When it comes to clinical phase II, these drugs often
fail because primary cancers do not proliferate as rapidly as cancer cell
Translational Oncology Vol. 7, No. 6, 2014 Improved efficacy of MMC treatment in NMIBC models Gederaas et al. 823lines [26]. Our group has previously demonstrated that the induction
of apoptosis and increased efficacy of ICL-inducing drugs caused by
ATX-101 is not S-phase dependent; however, normal cells are far less
sensitive than cancer cells [15]. Thus, ATX-101 likely increases the
efficacy of MMC in all cancer cells independent of their cycle phase,
and this is likely the reason for the good anticancer efficacy of the
MMC/ATX-101 combination observed also in the slow growing
cancers induced by BBN.
ATX-101 has previously been shown to reduce DNA repair and
increase apoptotic/cytotoxic responses to chemotherapeutics in vitro
and in vivo [10,11,15]. This study shows that ATX-101 penetrated
the bladder wall and increased the anticancer efficacy of intravesically
dosed bleomycin and MMC. The results are confirmed in two
fundamentally different orthotopic bladder cancer models in
immune-competent rats. The BBN model, which induced genetically
heterogeneous and slow growing cancers, is potentially more relevant
to the human bladder cancer disease than the AY-27 cancer cell line–
based model. Therefore, we regard the results observed in this model
as very promising and supportive for future clinic trials of ATX-101/
MMC in patients with NMIBC.
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